Pharma BD Deal Intelligence
Sanofi obtained worldwide (global) exclusive rights to develop, manufacture and commercialize Chia Tai Tianqing Pharmaceutical Group's (CTTQ, a subsidiary of Sino Biopharmaceutical Limited) rovadicitinib (Anxu) -- a first-in-class oral JAK/ROCK dual inhibitor -- for $135M upfront plus up to $1.395B in development, regulatory and sales milestones and up to double-digit tiered royalties on net sales. Rovadicitinib won its first approval in China (NMPA, February 2026) for first-line intermediate-2/high-risk myelofibrosis (PMF, post-PV-MF, post-ET-MF). Chronic graft-versus-host disease (cGVHD) is the lead expansion indication: a Phase III cGVHD trial is ongoing in China and the asset has been cleared for Phase 2 development in the US for cGVHD. The agreement, signed March 4, 2026, remains subject to customary closing conditions, including regulatory clearances.